

ONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing (Only for Continuation or Divisional applications under 37 CFR 1.53(d)) ☐ DUPLICATE

Address to:

Assistant Commissioner for Patents Box CPA Washington, DC 20231

CAMELLIA W. ADAMS, ET AL. First Inventor Group Art Unit Examiner

9491-013-27

This is a request for a

■ continuation or □ divisional application under 37 CFR 1.53(d)

(continued prosecution application (CPA)) of prior application number 09/138,091

Attorney Docket No.

filed on AUGUST 21, 1998

entitled AGONIST ANTIBODIES

□ Enter the unentered amendment previously filed

MELLIA ...

PECTOR L.

ar 37 CFR 1.53(d)

138,091

under 37 CFR 1.116 in the prior responsional application.

En 16002900

A preliminary amendment is enclosed.

☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4)

a. DELETE the following inventor(s) named in the prior nonprovisional application:

b.

The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.

5. Information Disclosure Statement (IDS) is enclosed:

a. □ PTO-1449

b.

Copies of IDS Citations

CLAIMS	NUMBER FILED			NUMBER EXTRA		RATE	CALCULATIONS
TOTAL	6	MINUS	20	0	×	\$18 =	\$0.00
INDEPENDENT	1	MINUS	3	0	×	\$78 =	\$0.00
		□ MULTIPLE DEPENDENT CLAIMS			+	\$260 =	\$0.00
	4.				B	ASIC FEE	\$690.00
		TOTAL OF ABOVE CALCULATIONS					\$690.00
		□ Reduction by 50% for filing by Small Entity					\$0.00
						TOTAL	\$690.00

6. Small Entity Status:

- a. □ A small entity statement is enclosed.
- b.

 A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c.

 Is no longer claimed.
- 7. The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 for the papers being filed herewith and for which no check is enclosed, or credit any overpayment to Deposit Account No. 50-1442.
 - If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time in the parent case. Any fees required for such an extension of time may be charged to Deposit Account No. 50-1442.
- A check in the amount of

\$690.00 is enclosed.

9. □ Other:

09/08/2000 CNGUYEN 00000020 09138091

01 FC:131

690.00 OP

Respectfully submitted,

PIPER MARBURY RUDNICK & WOLFE LLP

my Mill

Steven B. Kelber

Registration No.

30,073

Amy L. Miller

Registration No.

43,804

1200 Nineteenth Street, N.W. Washington, D.C. 20036-2412 Telephone No. (202) 861-3900 Facsimile No. (202) 223-2085

Docket No.

9491-013-27

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: CAMELLIA W. ADAMS, ET AL. GAU:

1647

SERIAL NO: 09/138,091

EXAMINER: SPECTOR, L.

FILING DATE: AUGUST 21, 1998

FOR:

AGONIST ANTIBODIES

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

RECEIVED
SEP 12 2000
TECH CENTER 1800/886

Prior to examination of the above-identified application, and to advance the prosecution thereof, please amend the above-identified application in the following manner.

IN THE CLAIMS:

Please cancel Claims 1-42

Please add the following new Claims 43-48.

- -43. An isolated nucleic acid encoding an agonist antibody, fragment, or variant thereof which binds to a thrombopoietin receptor.
- 44. The isolated nucleic acid of Claim 43, wherein said thrombopoietin receptor comprises mammalian empl.
- 45. The isolated nucleic acid of Claim 44, wherein said thrombopoietin receptor is human c-mpl.

▶6. A vector comprising the nucleic acid of Claim 43.

- 47. A host cell comprising the vector of Claim 46.
- 48. A method of producing an agonist antibody comprising culturing the host cell of Claim 47 under conditions wherein the nucleic acid is expressed.- -